XNASAKYA
Market cap139mUSD
Jan 17, Last price
2.82USD
1D
2.17%
1Q
-10.19%
IPO
-87.72%
Name
Akoya Biosciences Inc
Chart & Performance
P/E
—
P/S
1.45
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
97m
+29.09%
Net income
-63m
L-10.36%
CFO
-51m
L-4.85%
Earnings
Mar 03, 2025
Profile
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 96,633 29.09% | 74,859 36.31% | |||
Cost of revenue | 62,217 | 54,680 | |||
Unusual Expense (Income) | |||||
NOPBT | 34,416 | 20,179 | |||
NOPBT Margin | 35.62% | 26.96% | |||
Operating Taxes | 40 | 123 | |||
Tax Rate | 0.12% | 0.61% | |||
NOPAT | 34,376 | 20,056 | |||
Net income | (63,323) -10.36% | (70,641) 64.53% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 47,967 | 447 | |||
BB yield | -22.12% | -0.12% | |||
| Debt | |||||
Debt current | 6,896 | 3,629 | |||
Long-term debt | 92,710 | 84,662 | |||
Deferred revenue | 3,193 | 2,114 | |||
Other long-term liabilities | 5,765 | 6,039 | |||
Net debt | 16,481 | 6,770 | |||
| Cash flow | |||||
Cash from operating activities | (50,899) | (53,496) | |||
CAPEX | (3,653) | (7,360) | |||
Cash from investing activities | 3,347 | (14,079) | |||
Cash from financing activities | 56,844 | 28,726 | |||
FCF | 25,953 | 5,419 | |||
| Balance | |||||
Cash | 83,125 | 81,218 | |||
Long term investments | 303 | ||||
Excess cash | 78,293 | 77,778 | |||
Stockholders' equity | (230,069) | (166,752) | |||
Invested Capital | 381,951 | 309,270 | |||
ROIC | 9.95% | 7.05% | |||
ROCE | 22.65% | 14.15% | |||
| EV | |||||
Common stock shares outstanding | 44,435 | 37,747 | |||
Price | 4.88 -49.01% | 9.57 -37.49% | |||
Market cap | 216,841 -39.97% | 361,238 -36.95% | |||
EV | 233,322 | 368,008 | |||
EBITDA | 43,306 | 27,328 | |||
EV/EBITDA | 5.39 | 13.47 | |||
Interest | 8,761 | 4,554 | |||
Interest/NOPBT | 25.46% | 22.57% | |||